Gene therapy

Cell and gene therapy
#Gene therapy #Genetics / genomics #Hearing Loss #Regeneron Pharmaceuticals

Gene therapy brings “new era” in the treatment of hearing loss

New gene therapy trial results have shown dramatic and sustained improvements in hearing and speech perception in children with profound genetic hearing loss.  The updated data for Regeneron Pharmaceuticals’ investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were… Read More

#News #Trending News

Screening patient for AMD
#AMD #Clinical trial #Complement Therapeutics #FDA #Gene therapy #Geographic atrophy #Ophthalmology

FDA clears gene therapy trial in geographic atrophy

The US Food and Drug Administration (FDA) has cleared Complement Therapeutics’ Investigational New Drug (IND) application for CTx001, the company’s lead gene therapy candidate.   The IND clearance enables initiation of the Opti-GAIN Phase I/II clinical trial in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).   CTx001… Read More

#News #Regulatory

#Cancer research #Gene therapy #Long Covid

This week in Drug Discovery (29 September – 3 October)

News round-up for 29 September – 3 October by Bruno Quinney, Content Team at DDW.  This week’s news is led by the agreement by Genmab to acquire Merus in a deal worth approximately $8 billion, an announcement which could have important ramifications in cancer research. Scientists have… Read More

#News

#Antibodies #Gene therapy

Researchers develop new method for safer AAV gene therapies

Researchers at the HUN-REN Research Centre for Natural Sciences (HUN-REN TTK) have developed a new method for detecting neutralising antibodies (Nabs), offering the potential for safer and more successful AAV gene therapies.  The novel ‘Constant Serum Concentration’ (CSC) assay, published in the journal Nature Gene Therapy, correctly… Read More

#News

Gene therapy
#Gene editing #Gene therapy #Genetic diseases #Huntington's disease #uniQure

Trial shows slowing of Huntington’s progression for the first time

A global clinical trial for a new Huntington’s disease gene therapy has posted positive results, including 75% less progression of the disease.  AMT-130 is the first gene therapy to be tested in people with Huntington’s. This is also the first time a drug trial has reported continuing,… Read More

#News #Trending News

#AAV #Gene sequencing #Gene therapy #Nanopore sequencing

Download: A complete workflow for full-length AAV sequencing

Ensuring the integrity of adeno-associated virus (AAV) vectors is critical for gene therapy success, yet traditional methods can miss key structural elements. Download this new Workflow from Oxford Nanopore Technologies to discover how nanopore sequencing enables comprehensive characterisation of AAV genomes — including inverted terminal repeats (ITRs), transgenes, and… Read More

#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: The latest advances in advanced therapies discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar on 25 September will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#Clinical trial #Drug discovery #Gene therapy #Neuroscience #Parkinson's

AskBio begins second phase of gene therapy trial for Parkinson’s  

The first European patients have been randomised in a Phase II gene therapy clinical trial for Parkinson’s disease (PD), AskBio has announced.   The REGENERATE-PD clinical trial is evaluating the safety and efficacy of AskBio’s investigational gene therapy AB-1005 and will enrol approximately 87 patients across clinical trial… Read More

#Editor's Choice #News

#AAV #Gene sequencing #Gene therapy #Nanopore sequencing

A complete workflow for full-length AAV sequencing

Ensuring the integrity of adeno-associated virus (AAV) vectors is critical for gene therapy success, yet traditional methods can miss key structural elements. Discover how nanopore sequencing enables comprehensive characterisation of AAV genomes — including inverted terminal repeats (ITRs), transgenes, and promoters — all in a single workflow. Download this workflow… Read More

#Resources

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Register now to hear from the CGT experts

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar on 25 September will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: Challenges and solutions in CGT drug discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Eye health ophthalmology
#Clinical trials #Drug discovery #Gene therapy #Ophthalmology

Advancing gene-agnostic therapies for inherited retinal diseases 

DDW’s Megan Thomas speaks with Dr Arun Upadhyay, Chief Scientific Officer, Head of Research & Development at Ocugen, about the development of gene-agnostic modifier therapies for inherited retinal diseases, highlighting pathway discovery, preclinical models, dosing strategies, biomarker integration, and the potential expansion of this approach beyond ophthalmology.  MT: How does… Read More

#Exclusive Content #News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: Experts explore developments in CGT drug discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Watch now: Breaking barriers in cell and gene therapy

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Breaking barriers in cell and gene therapy

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#Webinars

#FDA #Gene therapy #Phase II trial #Rare disease #Rocket Pharmaceuticals

FDA lifts hold on Rocket Pharma’s Phase II trial of RP-A501

The US Food and Drug Administration (FDA) has lifted the clinical hold on Rocket Pharmaceuticals’ pivotal Phase II trial of RP-A501 for the treatment of Danon disease.  The hold was lifted in under three months and led to an increase in  Rocket’s stock value by 30%. … Read More

#News